Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

Abstract

Cancer therapies have advanced tremendously throughout the last decade, yet multiple factors still hinder the success of the different cancer therapeutics. The traditional therapeutic approach has been proven insufficient and lacking in the suppression of tumor growth. The simultaneous delivery of multiple small-molecule chemotherapeutic drugs and genes improves the effectiveness of each treatment, thus optimizing efficacy and improving synergistic effects. Nanomedicines integrating inorganic, lipid, and polymeric-based nanoparticles have been designed to regulate the spatiotemporal release of the encapsulated drugs. Multidrug-loaded nanocarriers are a potential strategy to fight cancer and the incorporation of co-delivery systems as a feasible treatment method has projected synergistic benefits and limited undesirable effects. Moreover, the development of co-delivery systems for maximum therapeutic impact necessitates better knowledge of the appropriate therapeutic agent ratio as well as the inherent heterogeneity of the cancer cells. Co-delivery systems can simplify clinical processes and increase patient quality of life, even though such systems are more difficult to prepare than single drug delivery systems. This review highlights the progress attained in the development and design of nano carrier-based co-delivery systems and discusses the limitations, challenges, and future perspectives in the design and fabrication of co-delivery systems.

Recent Advances in Nanoparticle-Mediated Co-Delivery System: A Promising Strategy in Medical and Agricultural Field

“…As for the fabrication of the co-delivery system, designers need to have a clear understanding of drugs and genes of each component, and fully consider the interactions between nanocarrier and cargo, as well as the synergies between loaded reagents [ 138 , 139 ]. For drug and gene co-delivery systems, the biological distribution and pharmacokinetics of the carried agents will be affected due to the huge differences in physicochemical properties of the two components loaded by NPs, such as the difference in molecular weight and hydrophilicity [ 140 ].…”

Combinational antitumor strategies of exosomes as drug carriers: Mini review

“…To achieve a high concentration of drugs at the local site, nanocarriers are modified to aggregate drugs in the tumor environment. Codelivery nanocarriers have become a newly emerging strategy to magnify synergistic effects and minimize adverse reactions (Al Bostami et al, 2022). We summarize current combinational antitumor plans based on exosomes and propose some views about future challenges and development (Figure 2; Supplementary Table S2).…”

Design and Fabrication of Anticancer Drug‐Loaded Poly(ϵ‐caprolactone)‐Poly(ethylene glycol)‐Poly(ϵ‐caprolactone) Micelles as Controlled Release System

“…Consequently, attention has been directed toward planning drug delivery systems to co-deliver various combinations of therapeutics agents to overcome the disadvantages of single-drug chemotherapy. [7] In previous work, we prepared PCEC polymeric micelles. [8] In the literature review, there is no study conducted with the DOX/PSC 833 or DOX/TPGS 1000 co-loaded PCEC drug delivery system.…”

“…Most of the time, the application of single‐drug chemotherapy, also known as monotherapy, is inadequate to provide a comprehensive therapeutics plan which is effective in treating cancer. Consequently, attention has been directed toward planning drug delivery systems to co‐deliver various combinations of therapeutics agents to overcome the disadvantages of single‐drug chemotherapy [7] …”